This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
We agree with some of the arguments of So et al.1 to justify the skepticism of “refractory” epilepsy centers.
Footnotes
Author contributions: Dr. Benbadis: original conceptualization, drafting, data collection and organization from NAEC, principal writing. Dr. Helmers: interpretation of the data, critical review of concepts and content, and editing. Dr. Hirsch: interpretation of the data, critical review of concepts and content, and editing. Dr. Sirven: interpretation of the data, critical review of concepts and content, and editing. Dr. Vale: critical review and input from surgical point of view and editing. Dr. Wheless: interpretation of the data, critical review of concepts and content, and editing.
Study funding: No targeted funding reported.
Disclosure: S. Benbadis has served as a consultant for Cyberonics, Lundbeck, RSC Diagnostics, Sunovion, Supernus, UCB Pharma, and Upsher-Smith; is on the speakers' bureau for Cyberonics, GlaxoSmithKline, Lundbeck, Sunovion, Supernus, and UCB Pharma; has received grant support from Cyberonics, Lundbeck, Sepracor, Sunovion, Supernus, UCB Pharma, and Upsher-Smith; has received royalties as an author or editor for Emedicine-Medscape-WebMD and UpToDate; and is on the editorial boards of Medscape-WebMD, European Neurology, Epileptic Disorders, Epilepsy and Behavior, and Expert Review of Neurotherapeutics. S. Helmers has served as a consultant for Cyberonics and UCB; has received grant support from Cyberonics and UCB; and has an IPA with the CDC. L. Hirsch has received research support from UCB, Upsher-Smith, and Lundbeck; has served as a consultant to Lundbeck, Upsher-Smith, RSC Diagnostics, Neuropace, and Natus; and has received royalties from UpToDate and for coauthoring Atlas of EEG in Critical Care (John Wiley & Sons, Inc., 2010). J. Sirven has received grant support from Neuropace, Cyberonics, Eisai, and Upsher-Smith; has served as consultant for Lundbeck, Sunovion, and Upsher-Smith; has received royalties from UpToDate, LWW, and time compensation from the Epilepsy Foundation for Epilepsy.com; and serves on the editorial board of Epilepsy & Behavior, Epilepsy Currents, and Mayo Clinic Proceedings. F. Vale reports no disclosures. J. Wheless has received grants from NH, Shainberg Foundation, GSK, Cyberonics, Eisai, Upsher-Smith, and Novartis; has served as a consultant for Lundbeck, Cyberonics, Pfizer, Eisai, Sunovion, Supernus, and Upsher-Smith; and has served on the speakers' bureau for Lundbeck, Questcor, Cyberonics, Eisai, and Supernus. Go to Neurology.org for full disclosures.
- © 2014 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
- Role of neurostimulation in the treatment of epilepsy
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
